Hidradenitis Suppurativa Market Share

North American Market Statistics

The Hidradenitis Suppurativa market in the North America region will have the biggest growth during the forecast period with a revenue share of around 37%. This growth will be noticed owing to the increasing adoption of the newest technologies to deal with hidradenitis suppurativa (HS) in this region. For instance, on October 31, 2023, Novartis A.G., an international leader in immuno-dermatology and rheumatology, declared that the US Food and Drug Administration (FDA) has accepted Cosentyx® (secukinumab) to cure lessen to massive hidradenitis suppurativa (HS) in adults. Cosentyx is the only FDA-licensed completely human biologic that straight inhibits interleukin-17A (IL-17A), a cytokine believed to be involved in the inflammation of HS.

APAC Market Analysis

The Hidradenitis Suppurativa market in the APAC region will also encounter huge growth during the forecast period and will hold the second position owing to the increasing frequency of obesity in this region. Although they are typically even lower, the corresponding numbers in the Eastern Hemisphere—primarily Asia—seem to be improving. Ma et al. provide strong evidence in this journal issue that China is seeing a very concerning rise in obesity, especially abdominal obesity. Given the magnitude of China's population and this growth, we are probably seeing an unprecedented development, at least to an extent.